Cardiorenal syndrome type 3: Pathophysiologic and epidemiologic considerations

Contributions to Nephrology

Volumn 182, Issue , 2013, Pages 137-157

  Bagshaw, Sean M ^a,j   Hoste, Eric A ^b   Braam, Branko ^a   Briguori, Carlo ^c   Kellum, John A ^d   McCullough, Peter A ^e,f,g,h   Ronco, Claudio ⁱ  

^a UNIVERSITY OF ALBERTA   (Canada)

^b GHENT UNIVERSITY   (Belgium)

^c Unit of Reproductive Medicine   (Italy)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e St John Providence Health System   (United States)

^f Medical Centers   (United States)

^g St John Macomb Oakland Hospital   (United States)

^h ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

ⁱ SAN BORTOLO HOSPITAL   (Italy)

^j UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM;

ACUTE KIDNEY FAILURE; ANIMAL; CARDIORENAL SYNDROME; CLASSIFICATION; CONSENSUS DEVELOPMENT; ELECTROCARDIOGRAPHY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ACUTE KIDNEY INJURY; ANIMALS; CALCIUM; CARDIO-RENAL SYNDROME; ELECTROCARDIOGRAPHY; HUMANS; HYPERTENSION; MYOCARDIAL ISCHEMIA; RENIN-ANGIOTENSIN SYSTEM;

EID: 84879071005     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000349971     Document Type: Review

References (88)

1. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008; 52:1527-1539.
2. Yap SC, Lee HT: Acute kidney injury and extrarenal organ dysfunction: new concepts and experimental evidence. Anesthesiology 2012; 116:1139-1148.
3. Kelly KJ: Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol 2003;14:1549-1558. (Pubitemid 36687056)
4. Prabhu SD: Cytokine-induced modulation of cardiac function. Circ Res 2004; 95:1140-1153. (Pubitemid 39648205)
5. Bozkurt B, Kribbs SB, Clubb FJ Jr, et al: Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97: 1382-1391. (Pubitemid 28182677)
6. Zager RA: Uremia induces proximal tubular cytoresistance and heme oxygenase-1 expression in the absence of acute kidney injury. Am J Physiol Renal Physiol 2009; 296:F362-F368.
7. Zager RA, Johnson AC, Lund S: Uremia impacts renal inflammatory cytokine gene expression in the setting of experimental acute kidney injury. Am J Physiol Renal Physiol 2009; 297:F961-F970.
8. Kingma JG Jr, Vincent C, Rouleau JR, Kingma I: Influence of acute renal failure on coronary vasoregulation in dogs. J Am Soc Nephrol 2006; 17:1316-1324. (Pubitemid 43673411)
9. Nishiyama J, Kobayashi S, Ishida A, et al: Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol 2000; 157:815-823. (Pubitemid 32109374)
10. Sharma UC, Pokharel S, van Brakel TJ, et al: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110:3121-3128. (Pubitemid 39492008)
11. Chuasuwan A, Kellum JA: Cardio-renal syndrome type 3: epidemiology, pathophysiology, and treatment. Semin Nephrol 2012; 32:31-39.
12. Anzai A, Anzai T, Naito K, et al: Prognostic significance of acute kidney injury after reperfused ST-elevation myocardial infarction: synergistic acceleration of renal dysfunction and left ventricular remodeling. J Card Fail 2010; 16:381-389.
13. Ronco C, McCullough P, Anker SD, et al: Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010; 31:703-711.
14. Ronco C, Kellum JA, Mehta R: Acute Dialysis Quality Initiative (ADQI). Nephrol Dial Transplant 2001; 16:1555-1558. (Pubitemid 32750444)
15. Kellum JA, Bellomo R, Ronco C: Acute Dialysis Quality Initiative (ADQI): methodology. Int J Artif Organs 2008; 31:90-93. (Pubitemid 351425006)
16. Perianayagam MC, Tighiouart H, Liangos O, et al: Polymorphisms in the myeloperoxidase gene locus are associated with acute kidney injury-related outcomes. Kidney Int 2012; 82: 909-919.
17. Payen D, Lukaszewicz AC, Legrand M, et al: A multicentre study of acute kidney injury in severe sepsis and septic shock: association with inflammatory phenotype and HLA genotype. PLoS One 2012; 7:e35838.
18. Frank AJ, Sheu CC, Zhao Y, et al: BCL2 genetic variants are associated with acute kidney injury in septic shock. Crit Care Med 2012; 40:2116-2123.
19. Lu JC, Coca SG, Patel UD, Cantley L, Parikh CR: Searching for genes that matter in acute kidney injury: a systematic review. Clin J Am Soc Nephrol 2009; 4:1020-1031.
20. Coca SG, Cho KC, Hsu CY: Acute kidney injury in the elderly: predisposition to chronic kidney disease and vice versa. Nephron Clin Pract 2011; 119(suppl 1):c19-c24.
21. Brown JR, Kramer RS, Coca SG, Parikh CR: Duration of acute kidney injury impacts long-term survival after cardiac surgery. Ann Thorac Surg 2010; 90:1142-1148.
22. Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE: The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 2011; 79:1361-1369.
23. Grams ME, Rabb H: The distant organ effects of acute kidney injury. Kidney Int 2012; 81: 942-948.
24. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B: The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005; 26:11-17. (Pubitemid 40221118)
25. Ma XL, Lefer DJ, Lefer AM, Rothlein R: Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion. Circulation 1992; 86:937-946.
26. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA: Leukocytes and the risk of ischemic diseases. JAMA 1987; 257: 2318-2324. (Pubitemid 17059605)
27. Kronon MT, Allen BS, Halldorsson A, Rahman S, Wang T, Ilbawi M: Dose dependency of L-arginine in neonatal myocardial protection: the nitric oxide paradox. J Thorac Cardiovasc Surg 1999; 118: 655-664. (Pubitemid 29474792)
28. Tracz MJ, Juncos JP, Croatt AJ, et al: Deficiency of heme oxygenase-1 impairs renal hemodynamics and exaggerates systemic inflammatory responses to renal ischemia. Kidney Int 2007; 72:1073-1080. (Pubitemid 47609038)
29. Hirota H, Yoshida K, Kishimoto T, Taga T: Continuous activation of gp130, a signal-transducing receptor component for interleukin-6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 1995; 92:4862-4866.
30. Blake P, Hasegawa Y, Khosla MC, Fouad-Tarazi F, Sakura N, Paganini EP: Isolation of 'myocardial depressant factor(s)' from the ultrafiltrate of heart failure patients with acute renal failure. ASAIO J 1996; 42:M911-M915. (Pubitemid 26363805)
31. Edmunds NJ, Lal H, Woodward B: Effects of tumour necrosis factor-α on left ventricular function in the rat isolated perfused heart: possible mechanisms for a decline in cardiac function. Br J Pharmacol 1999; 126:189-196. (Pubitemid 29041757)
32. Miyano H, Shishido T, Kawada T, et al: Acute effect of tumor necrosis factor-α is minimal on mechanics but significant on energetics in blood-perfused canine left ventricles. Crit Care Med 1999; 27:168-176. (Pubitemid 29052833)
33. Rauchhaus M, Doehner W, Francis DP, et al: Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102:3060-3067.
34. Anker SD, Coats AJ: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86:123-130. (Pubitemid 35284800)
35. Wen X, Peng Z, Li Y, et al: One dose of cyclosporine A is protective at initiation of folic acid-induced acute kidney injury in mice. Nephrol Dial Transplant 2012; 27: 3100-3109.
36. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD: Myocardial protection by brief ischemia in noncardiac tissue. Circulation 1996; 94:2193-2200. (Pubitemid 26360513)
37. Verdouw PD, Gho BC, Koning MM, Schoemaker RG, Duncker DJ: Cardioprotection by ischemic and nonischemic myocardial stress and ischemia in remote organs. Implications for the concept of ischemic preconditioning. Ann NY Acad Sci 1996; 793:27-42. (Pubitemid 26402583)
38. Kobuchi S, Tanaka R, Shintani T, et al: Mechanisms underlying the renoprotective effect of GABA against ischemia/reperfusion-induced renal injury in rats. J Pharmacol Exp Ther 2011; 338:767-774.
39. Li C, Zhang D, Han S, et al: Synthesis, electronic properties, and applications of indium oxide nanowires. Ann NY Acad Sci 2003; 1006:104-121. (Pubitemid 38064779)
40. Singh K, Xiao L, Remondino A, Sawyer DB, Colucci WS: Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol 2001; 189: 257-265. (Pubitemid 33063293)
41. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52:11-34. (Pubitemid 30127593)
42. Kajstura J, Cigola E, Malhotra A, et al: Angio-tensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 1997; 29:859-870. (Pubitemid 27196513)
43. Kawano H, Do YS, Kawano Y, et al: Angio-tensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000; 101:1130-1137. (Pubitemid 30146614)
44. Desai KV, Laine GA, Stewart RH, et al: Mechanics of the left ventricular myocardial in-terstitium: effects of acute and chronic myo-cardial edema. Am J Physiol Heart Circ Physiol 2008;294:H2428-H2434.
45. Nath KA, Grande JP, Croatt AJ, et al: Trans-genic sickle mice are markedly sensitive to renal ischemia-reperfusion injury. Am J Pathol 2005; 166:963-972. (Pubitemid 40528439)
46. Robinson SC, Bowmer CJ, Yates MS: Cardiac function in rats with acute renal failure. J Pharm Pharmacol 1992; 44:1007-1014.
47. Kelly KJ, Meehan SM, Colvin RB, Williams WW, Bonventre JV: Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney International 1999; 56:922-931. (Pubitemid 29411719)
48. Wencker D, Chandra M, Nguyen K, et al: A mechanistic role for cardiac myocyte apopto-sis in heart failure. J Clin Invest 2003; 111: 1497-1504. (Pubitemid 38063282)
49. Le NT, Richardson DR: The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 2002; 1603:31-46. (Pubitemid 35257983)
50. Liu YH, D'Ambrosio M, Liao TD, et al: N-acetyl-seryl-aspartyl-lysyl- proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009; 296:H404-H412.
51. Wiedemann HP, Wheeler AP, Bernard GR, et al: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564-2575. (Pubitemid 43882352)
52. Arikan AA, Zappitelli M, Goldstein SL, Nai-paul A, Jefferson LS, Loftis LL: Fluid overload is associated with impaired oxygenation and morbidity in critically ill children. Pediatr Crit Care Med 2012; 13:253-258.
53. Bouchard J, Soroko SB, Chertow GM, et al: Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 2009; 76:422-427.
54. Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL: A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 2008; 12:R74.
55. Grams ME, Estrella MM, Coresh J, Brower RG, Liu KD: Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol 2011; 6:966-973.
56. Bellomo R, Cass A, Cole L, et al, RENAL Replacement Therapy Study Investigators: An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Crit Care Med 2012; 40:1753-1760.
57. Ip JE, Cheung JW, Park W: Temporal associations between thoracic volume overload and malignant ventricular arrhythmias: a study of intrathoracic impedance. J Cardio-vasc Electrophysiol 2011; 22:293-299.
58. Davis KL, Laine GA, Geissler HJ: Effects of myocardial edema on the development of myocardial interstitial fibrosis. Microcirculation 2000; 7:269-280.
59. Nazar A, Guevara M, Sitges M, et al: LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol 2013; 58:51-57.
60. Legrand M, Darmon M, Joannidis M, Payen D: Management of renal replacement therapy in ICU patients: an international survey. Intensive Care Med 2013; 39:101-108.
61. Bellomo R, Cass A, Cole L, et al: Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361: 1627-1638.
62. Nimmo AJ, Than N, Orchard CH, Whitaker EM: The effect of acidosis on β-adrenergic receptors in ferret cardiac muscle. Exp Physiol 1993; 78:95-103. (Pubitemid 23056785)
63. Bagshaw SM, Wald R, Barton J, et al: Clinical factors associated with initiation of renal replacement therapy in critically ill patients with acute kidney injury-a prospective multicenter observational study. J Crit Care 2012; 27:268-275.
64. Palevsky PM, Zhang JH, O'Connor TZ, et al: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359:7-20. (Pubitemid 351931092)
65. Schwenger V, Weigand MA, Hoffmann O, et al: Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury-a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care 2012; 16:R140.
66. Zazzo JF, Troche G, Ruel P, Maintenant J: High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function. Intensive Care Med 1995; 21:826-831.
67. Demirjian S, Teo BW, Guzman JA, et al: Hypophosphatemia during continuous hemodialysis is associated with prolonged respiratory failure in patients with acute kidney injury. Nephrol Dial Transplant 2011; 26:3508-3514.
68. Duranton F, Cohen G, De Smet R, et al: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012; 23: 1258-1270.
69. Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G: An update on uremic toxins. Int Urol Nephrol 2013; 45: 139-150.
70. Littmann L, Monroe MH, Taylor L 3rd, Brearley WD Jr: The hyperkalemic Brugada sign. J Electrocardiol 2007; 40:53-59. (Pubitemid 44958611)
71. Marques JS, Diogo AN: Dead man walking: an extreme case of sinusoidal wave pattern in severe hyperkalemia. J Am Coll Cardiol 2012; 59:2118.
72. Shannon TR, Pogwizd SM, Bers DM: Elevated sarcoplasmic reticulum Ca #sup#2+#/sup# leak in intact ventricular myocytes from rabbits in heart failure. Circ Res 2003; 93:592-594. (Pubitemid 37222154)
73. Schulz R, Panas DL, Catena R, Moncada S, Olley PM, Lopaschuk GD: The role of nitric oxide in cardiac depression induced by interleukin-1β and tumour necrosis factor-α. Br J Pharmacol 1995; 114:27-34.
74. Tune JD, Gorman MW, Feigl EO: Matching coronary blood flow to myocardial oxygen consumption. J Appl Physiol 2004; 97:404-415. (Pubitemid 38802544)
75. Ronco C, Cruz D, Noland BW: Neutrophil gelatinase-associated lipocalin curve and neutrophil gelatinase-associated lipocalin extended-range assay: a new biomarker approach in the early diagnosis of acute kidney injury and cardio-renal syndrome. Seminars in nephrology 2012; 32:121-128.
76. Mishra J, Ma Q, Prada A, et al: Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14:2534-2543. (Pubitemid 37169339)
77. Haase M, Haase-Fielitz A, Bellomo R, Mertens PR: Neutrophil gelatinase-associated lipocalin as a marker of acute renal disease. Curr Opin Hematol 2010.
78. Schmidt-Ott KM, Mori K, Li JY, et al: Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007; 18:407-413. (Pubitemid 46193306)
79. Cruz DN, Gaiao S, Maisel A, Ronco C, Devarajan P: Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systematic review. Clin Chem Lab Medicine 2012; 50:1533-1545.
80. Yndestad A, Landro L, Ueland T, et al: Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009; 30:1229-1236.
81. Ding L, Hanawa H, Ota Y, et al: Lipocalin-2/neutrophil gelatinase-B associated lipocalin is strongly induced in hearts of rats with autoimmune myocarditis and in human myocarditis. Circ J 2010; 74:523-530.
82. Carlsson AC, Larsson A, Helmersson-Karlqvist J, et al: Urinary kidney injury molecule 1 and incidence of heart failure in elderly men. Eur J Heart Fail 2012 (E-pub ahead of print).
83. Scheuer J, Stezoski W: The effects of uremic compounds on cardiac function and metabolism. J Mol Cell Cardiol 1973; 5:287-300.
84. James MT, Ghali WA, Knudtson ML, et al: Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation 2011; 123: 409-416.
85. Selby NM, Kolhe NV, McIntyre CW, et al: Defining the cause of death in hospitalised patients with acute kidney injury. PLoS One 2012; 7:e48580.
86. Thakar CV, Christianson A, Himmelfarb J, Leonard AC: Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol 2011; 6: 2567-2572.
87. James MT, Hemmelgarn BR, Wiebe N, et al: Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet 2010; 376:2096-2103.
88. Acute Dialysis Quality Initiative (ADQI). www.ADQI.org (accessed January 10, 2013).